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RESUMO
Implante Percutâneo de Stent em Artérias Carótidas e 
Vertebrais: Dados do REMAT (Registro Madre Teresa)
Introdução: O acidente vascular encefálico (AVE) é a principal 
causa de morbidade e mortalidade no Brasil. Entre 10% e 30% 
dos AVEs estão associados à doença carotídea e 8%, à artéria 
vertebral. O tratamento endovascular das lesões extracranianas 
é alternativa à endarterectomia. Analisamos os resultados e 
avaliamos os preditores de eventos adversos em pacientes 
submetidos a angioplastia carotídea e vertebral com implante 
de stents. Métodos: Incluídos assintomáticos com lesão > 70% 
ou sintomáticos com lesão > 50% em artérias carótidas e sin-
tomáticos com lesão > 70% em artérias vertebrais. Avaliamos 
desfecho primário, definido como a incidência combinada 
de morte relacionada ou não ao procedimento, AVE maior, 
AVE menor ou infarto agudo do miocárdio (IAM). Resultados: 
Realizadas 224 intervenções com implante de stents em 199 
pacientes consecutivos, com predomínio do sexo masculino 
(73,9%), idade de 69,8 ± 9,9 anos e 37,7% eram diabéticos. 
Pacientes sintomáticos representaram cerca de dois terços 
dos casos e as lesões mais tratadas foram as lesões de novo 
(96,4%). As artérias carótidas internas esquerda (46%) e direita 
(44,6%) foram os vasos mais abordados. Desfecho combinado 
primário ocorreu em 5%, mortalidade relacionada ao procedi-
mento em 1%, mortalidade não-relacionada ao procedimento 
em 1%, AVE menor em 1,5% e IAM em 1,5%. Pacientes com 
antecedente de doença arterial coronária mostraram chance de 
apresentar desfecho primário 4 vezes maior [odds ratio (OR) 
4,32, intervalo de confiança de 95% (IC 95%) 1,09-17,21; 
P = 0,038]. Conclusões: Em nosso estudo obtivemos alto ín-
dice de sucesso e baixa ocorrência de eventos adversos, que 
demonstram a segurança e a eficácia do implante percutâneo 
de stent em artérias carótidas e vertebrais.
DESCRITORES: Acidente vascular cerebral. Artérias carótidas. 
Estenose das carótidas. Angioplastia. Stents.
ABSTRACT
Background: Stroke remains the leading cause of morbidity 
and mortality in Brazil. Epidemiological data suggest that 10% 
to 30% of all strokes are due to atherosclerotic carotid artery 
disease and 8% due to vertebral artery disease. Endovascular 
treatment of extracranial lesions is an alternative to endarter-
ectomy. We evaluated the results and predictors of adverse 
events in patients undergoing carotid and vertebral artery 
stenting. Methods: Asymptomatic patients with lesion > 70% 
or symptomatic patients with lesions > 50% in carotid arter-
ies and symptomatic patients with lesion > 70% in vertebral 
arteries were included. We evaluated the primary endpoint, 
defined as the composite incidence of death (procedural or 
non-procedural), major stroke, minor stroke or myocardial 
infarction (MI). Results: Two hundred and twenty-four interven-
tions with stenting were performed in 199 consecutive patients 
with a prevalence of males (73.9%), 69.8 ± 9.9 years of age 
and 37.7% were diabetics. Symptomatic patients represented 
about two thirds of the cases and the most commonly treated 
lesions were de novo lesions (96.4%). The left (46%) and 
right (44.6%) internal carotid arteries were the most com-
monly approached vessels. Composite primary endpoint was 
observed in 5% of the patients, procedure-related mortality 
in 1%, non-procedure related mortality in 1%, minor stroke 
in 1.5% and MI in 1.5%. Patients with a history of coronary 
artery disease had a 4-fold probability of presenting the primary 
endpoint [odds ratio (OR) 4.32, 95% confidence interval (CI 
95%) 1.09-17.21); P = 0.038]. Conclusions: In our study we 
obtained a high success rate and had a low rate of adverse 
events, demonstrating the safety and efficacy of percutaneous 
stent implantation in the carotid and vertebral arteries.
 
 
 
DESCRIPTORS: Stroke. Carotid arteries. Carotid stenosis. 
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S troke remains the third leading cause of death in industrialized countries, and the leading cause of adult disability.1 In the United States, it is esti-
mated that 795,000 strokes occur each year, generating 
direct and indirect costs of treating stroke victims of 
approximately US$ 68.9 billion annually.1,2 In Brazil, 
it is estimated that 250,000 strokes occur per year, 
representing the main cause of morbidity and mortality 
in the population.3
Extracranial cerebrovascular disease is an important 
cause of stroke and transient ischemic attack (TIA).4,5 
Epidemiological data suggest that 10% to 30% of strokes 
are due to carotid artery disease and 8% are associated 
with vertebral artery territory. The most common cause 
is atherosclerosis, but fibromuscular dysplasia, media 
cystic necrosis, arteritis, and dissection are also pres-
ent. Stroke and TIA may appear as a consequence of 
several mechanisms originating in the atherosclerotic 
plaque, such as thrombus embolism formation on the 
atherosclerotic plaque, flow reduction in a stenotic or 
occlusive plaque, atheroembolism, and subintimal dis-
section or hematoma.1
Endovascular treatment of carotid and vertebral 
artery obstructions is a constantly evolving technique 
and an alternative to endarterectomy in the preven-
tion of strokes. In recent years, with the development 
of catheters, stents, and cerebral protection devices, 
expansion of the indications for angioplasty in the 
carotid and vertebral territories has been sought, in 
order to minimize procedure-related risks. The evidence 
supporting stenting in carotid arteriesvs endarterectomy 
come from studies such as Stenting and Angioplasty 
with Protection in Patients at High Risk for Endarterec-
tomy Trial (SAPPHIRE),6,7 and Carotid Revascularization 
Endarterectomy vs. Stenting Trial (CREST),8,9 demonstrat-
ing results comparable to those of surgical treatment. 
However, in relation to angioplasty in vertebral arteries, 
the evidence is scarce. The only randomized study that 
compared endovascular treatment vs. clinical treatment 
in vertebral arteries1 was the Carotid And Vertebral Ar-
tery Transluminal Angioplasty Study (CAVATAS) study,10 
which showed no significant difference in the outcomes 
between the two patient groups.
This study aimed to evaluate the results and deter-
mine predictors of adverse clinical events in patients 
undergoing carotid and vertebral angioplasty with 
stenting in this service.
METHODS
Patients
Between January of 2006 and January of 2012, 
225 interventions were performed with 226 stent im-
plantations in the carotid or vertebral arteries, in 200 
consecutive patients admitted to the Hemodynamics 
and Interventional Cardiology Service of Hospital Madre 
Teresa (Belo Horizonte, MG, Brazil). Patients of both 
genders were enrolled, aged > 18 years, symptomatic 
in the last six months, with lesions > 50% in ipsilateral 
carotid artery, asymptomatic with lesions > 70% in the 
carotid artery, or symptomatic in the last six months 
with lesions > 70% in the vertebral artery. A patient 
diagnosed with pseudoaneurysm of the internal left 
carotid artery, in which a coated stent was used, was 
excluded from the analysis to ensure sample homogene-
ity, there by yielding a final sample of 224 interventions 
in 199 patients.
This study is in accordance with the Declaration 
of Helsinki and was approved by the Ethics Committee 
of the institution.
Angioplasty procedure and protocol
All procedures were performed electively at the 
Hemodynamics Laboratory of the Hospital Madre Te-
resa. All patients received acetylsalicylic acid at a dose 
of 100  mg/day and clopidogrel at a dose of 75 mg/
day, starting at least four days before the procedure. 
Acetylsalicylic acid was maintained indefinitely, and 
clopidogrel was maintained for at least 30 days after 
the intervention.
The interventions were performed by femoral access 
route in all patients under local anaesthesia with the 
Seldinger technique, using 6F or 7F sheaths. Antico-
agulation was attained with administration of 100 U/kg 
of unfractionated heparin, aiming to achieve activated 
clotting time between 250-300 seconds. The use of 
sedatives was avoided in order to prevent impairment 
of patient neurological assessment during the procedure. 
The guide-catheters used in most procedures were JR4 
or AL1, and long hydrophilic sheaths were used.
Stent implantations in the carotid and vertebral 
arteries was performed in accordance with the current 
guidelines, by experienced interventional cardiologists 
proficient in non-coronary procedures, board-certified 
by the Brazilian Society of Hemodynamics and In-
terventional Cardiology (Sociedade Brasileira de He-
modinâmica e Cardiologia Intervencionista – SBHCI). 
In all carotid procedures, a distal embolic protection 
filter was employed. Pre-dilation of carotid lesions was 
employed only in sub-occlusive and calcified lesions. 
After positioning and releasing the endoprosthesis, 
intravenous atropine was administered at a dose of 
0.5 mg to 1 mg, and post-dilation was performed in 
most cases with balloon inflation for complete stent 
expansion. The following stents were used: Precise, 
BX Velocity/Sonic, Presillion, and Palmaz – Genesis 
(Cordis Endovascular – Miami Lakes, United States); 
Wallstent, Express, and Liberté (Boston Scientific 
– Natick,USA); Protégé (ev3 Endovascular Inc. – 
Plymouth, United States); Multi-link Ultra and Xact 
(Abbott Vascular – Abbott Park, USA); and Dynamic 
(Biotronik Corporation – Berlin, Germany).
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For the angioplasty of vertebral arteries, a similar 
technique to that employed in the coronary arteries was 
used, by performing pre-dilation in complex lesions and 
coronary or peripheral stent implantation, depending 
on the artery calibre.
Final control angiography and brain circulation 
angiography were performed in all patients. After con-
firmation of the angiographic success, the procedure 
was closed and the patient was referred to the intensive 
care unit (ICU). In the absence of complications, the 
patients were released to the infirmary or apartment, were 
discharged on the following day, and were instructed to 
return within a month to undergo a consultation with 
the attending physician and/or Hemodynamics Service 
for clinical follow-up.
Outcomes and definitions
Neurological events were defined as: TIA, any 
neurological deficit reversed in the first 24 hours post-
procedure that did not result in residual neurological 
damage, including amaurosis fugax; minor stroke, new 
neurological event that resulted in a mild decrease of 
neurological function, not disabling or with minimal 
neurological sequelae; and major stroke, with estab-
lished neurological damage, disabling, and/or classified 
as 9 points on the National Institutes of Health Stroke 
Scale (NIHSS).4,9,12
The diagnosis of acute MI was based on elevation 
of markers of myocardial necrosis (CK-MB or troponin) 
two-fold higher than the normal limit, requested when 
the patient showed signs and symptoms consistent 
with myocardial ischemia or ischemic alterations on 
electrocardiography, routinely performed in the ICU.9,13
Angiographic success was defined as residual lesion 
< 30% by quantitative angiography in the absence of 
thrombi or dissections. Procedural success was defined 
as angiographic success in the absence of TIA, minor 
or major stroke or death related to the procedure.
A primary clinical outcome was evaluated in the 
follow-up period, defined as the composite incidence 
of death related or not to the procedure, major stroke, 
minor stroke, or acute MI. A secondary clinical outcome, 
defined as the composite occurrence of TIA/amaurosis 
fugax, significant bleeding that required blood transfu-
sion, or bradycardia requiring a temporary pacemaker, 
was also evaluated.
Statistical Analysis
Data tabulation was performed in Microsoft Excel, 
and STATA software, version 12.0, was used for the 
statistical analysis.
The descriptive results were obtained using fre-
quencies and percentages for categorical variables and 
measures of central tendency (means and medians) and 
measures of dispersion (standard deviations) for the 
quantitative variables.
Univariate analysis was performed to verify the 
association of clinical and angiographic variables with 
primary and secondary outcomes. All variables with P-
value < 0.20 in the univariate analysis were included 
in the initial model of the multivariate analysis using 
logistic regression with the forward method, that is, 
with the inclusion of variables in the model one by 
one, from the most significant to the least significant. 
The variables with a level of significance < 5% were 
maintained in the final model. The Hosmer-Lemeshow 
test was used to verify the adequacy of the model.
RESULTS
Regarding the clinical characteristics, the present 
study had a predominantly male population (73.9%), 
aged 38 to 90 years, with a mean age of 69.8 ± 9.9 
years, 37.7% diabetics, and 9.6% with renal failure. 
On admission, approximately two-thirds (68.8%) of 
patients were symptomatic, 44.7% with stroke and 
24.1% with previous TIA, and the minority had carotid 
murmur (6%). The most often treated lesions were de 
novo lesions (96.4%), as well as post-endarterectomy 
restenotic lesions, actinic lesions, post-trauma dissec-
tion, and Takayasu’s arteritis (Table 1).
The degree of stenosis of the target lesion was, on 
average, 74.8% ± 9.5%; lesions of 70% to 89% were 
the most often treated, corresponding to 80.8% of the 
patients. In addition, 26.8% of the patients had lesion 
> 70% in a vessel contralateral to the target vessel, 
12.5% of which were total occlusions. The left internal 
carotid artery was the most often treated vessel (46%), 
followed by the right internal carotid artery (44.6%), 
the left vertebral artery (3.6%), the left common carotid 
artery (3.1%), the right common carotid artery (2.2%), 
and the right vertebral artery (0.5%). Angiographic suc-
cess was attained in all procedures, and the clinical 
success rate was 95.1% (Table 2).
A total of 225 stents were used in the 224 interven-
tions. Precise stent (n = 106) was chosen for most of the 
stenting procedures, followed by Wall stent (n = 100), 
and Liberté stent (n = 8), used in the vertebral arteries. 
The other endoprostheses used were the Express (n = 
3),Presillion (n = 2), BX Velocity/Sonic (n = 1),Palmaz-
Genesis (n = 1), Protegé (n = 1),Multi-link Ultra (n = 
1), Xact (n = 1), and Dynamic (n = 1) stents. In one 
of the patients, it was necessary to implant two stents 
during the same intervention, a Wall stent overlapping 
a Precise stent in the right internal carotid artery to 
treat a segmental lesion.
The follow-up period was, on average, 2.2 ± 7.5 
months, with 70.1% of patients followed for up to one 
month, 20.5%for up to six months, and 9.4% for 12 
months or more. The incidence of the primary composite 
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outcome was 5%, with procedure-related mortality of 
1%, mortality unrelated to procedure of 1%, minor 
stroke of 1.5%, and MI of 1.5%. There were no major 
strokes. TIA/amaurosis fugax and significant bleeding 
requiring blood transfusion occurred in 3% and 4.5% 
of cases, respectively. The combined rate of primary and 
secondary outcomes was 12.6%. No complications were 
observed in femoral artery access route requiring surgical 
intervention. There was no symptomatic or prolonged 
bradycardia requiring temporary pacemaker (Table 3).
Multivariate analysis elucidates independent predic-
tors of adverse events (Table 4). The procedures with 
patients who had coronary artery disease demonstrated a 
four-fold higher chance of presenting primary outcomes 
(odds ratio [OR]: 4.32; 95% confidence interval [95% 
CI]: 1.09 to 17.21; P = 0.038). In addition, female 
gender (OR: 3.74; 95% CI: 1.13 to 12.35; P = 0.03), 
family history of stroke (OR: 8.04; 95% CI: 1.20 to 
53.83; P = 0.032) and renal failure (OR: 9.53; 95% 
CI: 2.54 to 35.63; P = 0.001) were predictors of the 
secondary outcome. In procedures whose patients had 
family history of stroke (OR: 5.50; 95% CI: 1.15 to 
26.36; P  =  0.033), and renal failure (OR: 6.16; 95% 
TABLE 1  
Clinical characteristics
Variable
n = 199 
patients/ 224 
lesions
Age, years 69.8 ± 9.9
Male gender, n (%) 147 (73.9)
Arterial hypertension, n (%) 164 (82.4)
Diabetes, n (%) 75 (37.7)
Dyslipidaemia, n (%) 86 (43.2)
Smoking, n (%) 24 (12.1)
Coronary artery disease, n (%) 82 (41.2)
Renal failure, n (%) 19 (9.6)
Family history of stroke, n (%) 8 (4)
Clinical picture, n (%)
Asymptomatic 62 (31.2)
Previous stroke 89 (44.7)
Previous transient ischemic 
accident 
48 (24.1)
Carotid murmur, n (%) 12 (6)
Types of lesion, n (%)
De novo 216 (96.4)
Restenotic (post-endarterectomy) 4 (1.8)
Actinic 2 (0.9)
Dissection 1 (0.5)
Takayasu’s arteritis 1 (0.5)
TABLE 2  
Angiographic and procedural characteristics
Variable
n = 199 
patients/ 
224 lesions
Treated artery, n (%)
Left internal carotid artery 103 (46)
Right internal carotid artery 100 (44.6)
Left vertebral artery 8 (3.6)
Left common carotid artery 7 (3.1)
Right common carotid artery 5 (2.2)
Right vertebral artery 1 (0.5)
Diameter of stenosis in the target vessel, % 74.8 ± 9.5
Diameter of stenosis in the target vessel,  
n (%)
50% to 69% 6 (2.7)
70% to 89% 181 (80.8)
90% to 99% 37 (16.5)
Diameter of stenosis in the contralateral 
vessel, n (%)
70% to 99% 32 (14.3)
100% 28 (12.5)
Sucesso angiográfico por Angiographic 
success, n (%)
224 (100)
Clinical success, n (%) 213 (95.1)
TABLE 3  
Adverse clinical events
Variable
n = 199 
patients
Primary outcome, n (%) 10 (5)
Procedure-related death 2 (1)
Death unrelated to procedure 2 (1)
Major stroke 0
Minor stroke 3 (1.5)
Acute myocardial infarction 3 (1.5)
Secondary outcome, n (%) 15 (7.5)
Transient ischemic attack 6 (3)
Significant bleeding 9 (4.5)
Composite primary and secondary 
outcomes, n (%)
25 (12.6)
CI: 2.11 to 17.97; P = 0.001) composite primary or 
secondary outcomes were more likely to occur. This 
registry showed no association between the presence 
or absence of pre-procedure symptoms in relation to 
the primary or secondary outcomes.
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DISCUSSION
The data presented in this cross-sectional, observa-
tional, and clinical study disclosed relevant aspects on 
the profile and outcome of patients undergoing percu-
taneous stent implantation in the carotid and vertebral 
arteries in a philanthropic tertiary care center, a refer-
ence in the treatment of high-complexity cardiovascular 
diseases in the metropolitan region of Belo Horizonte, 
state of Minas Gerais, Brazil. 
It is was observed that the information concerning 
the clinical characteristics of the assessed population, 
including age, gender, and traditional risk factors for 
atherosclerosis, were consistent with those observed 
in other studies.6-10 A high proportion of symptomatic 
patients (68.8%) and with target vessel lesion > 70% 
at admission, which was the expected profile of can-
didates for the intervention, was also observed.6,14,15 
Regarding the approach of special patient populations, 
such as patients with post-endarterectomy restenosis, 
with lesions after cervical irradiation, or inflammatory 
arteritis, the intervention remains a challenge, since 
such lesions have intense fibrosis, which can hinder 
stent expansion. Series of cases have reported greater 
difficulty for endarterectomy, with higher safety of per-
cutaneous stent implantation in this group of patients 
despite a higher rate of restenosis.1,16 The use of stent in 
dissection lesions is reserved for symptomatic patients 
who do not respond toanticoagulation.1 The present 
angiographic data are analogous to previously published 
works.6-10,17,18 In the CREST trial,8,9 however, the rate of 
occlusion of vessel contralateral to the target vessel was 
2.7%, whereas in the present study the proportion of 
total occlusion of the contralateral vessel was 12.5%.
Regarding the outcome analysis, there was a high 
clinical success rate (95.1%) and a low percentage of 
adverse clinical events, a fact probably attributed to 
the expertise of the interventional cardiologists with 
cerebrovascular interventions, since the learning curve 
acquired with the volume of procedures decisively 
influences the results of percutaneous intervention in 
the cerebrovascular territory.6-9,19 It is worth noting the 
low rates of adverse clinical events during follow-up 
in relation to other studies.6-9,20 In the present, the 
percentage of primary outcomes (death/stroke/acute MI) 
was 5%. In the periprocedural period of the SAPPHIRE6 
and CREST8,7,9 trials, the incidence of primary adverse 
events in patients undergoing angioplasty was 4.4% 
and 5.2%, respectively.
Since stroke is the leading cause of mortality in 
Brazil and a large number of stroke cases are attrib-
uted to vertebral and carotid atherosclerotic disease, 
its treatment can reduce the disabling sequelae and 
risk of death, offering greater expectation and better 
quality of life for the patient. From the social policies 
stand point, the timely intervention during the course of 
carotid and vertebral artery stenosis would represent the 
rescue of a portion of the population that uses primary 
and secondary health care services, as well as reducing 
costs for the tax payers, given that atherosclerosis in 
the cerebrovascular territory is part of a continuum, in 
which the progress of the disease is directly related to 
the population’s aging process.1 It is estimated that, in 
2025, Brazil will have a contingent of more than 30 
million individuals older than 60 years of age, constitut-
ing the seventh largest elderly population in the world, 
which represents21 thousands of stroke victims that will 
require medical assistance.
Considering the magnitude of the problem in 
Brazil, little attention is given from the authorities to 
public policies for stroke prevention and health system 
organisation. The rate of stroke in Brazilis higher than 
that in developed countries and the countries of South 
America; it is the fourth highest rate among all Latin 
American countries.22,23 Epidemiological data, however, 
suggest a tendency to the decrease in the stroke mortality 
rate in Brazil in recent years.23 The possible causes of 
the reduction in stroke mortality rate are related to the 
control of risk factors, improvement of the population’s 
TABLE 4  
Independent predictors of primary and secondary outcomes
Events
Primary outcomesa (n = 10)
Secondary outcomesb 
(n = 15)
Primary and secondary 
outcomesc (n = 25)
OR 95%CI P OR 95%CI P OR 95%CI P
Female gender N/D N/D N/D 3.74 1.13-12.35 0.03 N/D N/D N/D
Coronary artery disease 4.32 1.09-17.21 0.038 N/D N/D N/D N/D N/D N/D
Family history of stroke N/D N/D N/D 8.04 1.20-53.83 0.032 5.50 1.15-26.36 0.033
Renal failure N/D N/D N/D 9.53 2.54-35.63 0.001 6.16 2.11-17.97 0.001
Hosmer-Lemeshow test: aP = 0.250; bP = 0.692; cP = 0.273.
95% CI, 95% confidence interval; N/A, (not available) indicates that the variable was not included in the multivariate model; OR, odds ratio.
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socioeconomic status, development of diagnostic meth-
ods, and incorporation of high-tech procedures, such 
as cerebrovascular angioplasty by the Brazilian Unified 
Health System (Sistema Único de Saúde).
The endovascular treatment of obstructions in the 
carotid and vertebral arteries is a technique undergo-
ing constant improvement, and it is an alternative to 
endarterectomy in the prevention of brain ischemic 
events. Although the evidence regarding the angioplasty 
in vertebral arteries is still scarce, in recent years, with 
the development of catheters, stents, and devices for 
cerebral protection, the indications of angioplasty in 
the carotid territory have expanded, minimising the 
procedure-related risks. The evidence that supports 
carotid angioplasty vs. Endarterectomy is based on the 
results of large registries and randomized clinical trials, 
such as SAPPHIRE6,7 and CREST,8,9 which allowed for the 
consolidation of percutaneous stenting in the carotid 
arteries as a class I recommendation, level of evidence 
B, for symptomatic patients with stenosis ≥ 50% to 99%, 
and as class IIb recommendation, level of evidence B, 
in a symptomatic patients with stenosis ≥ 70% to 99%, 
according to the latest guideline from the United States, 
developed by a multidisciplinary task force.1
Study limitations
The study limitations are the retrospective analysis 
of data, the fact that it was conducted in a single center, 
and the short period of follow-up after hospital discharge. 
The multivariate analysis detected the probable indepen-
dent predictors of adverse events; however, due to the 
amplitude of the confidence intervals, a consequence of 
the low frequency of the analysed events, little can be 
affirmed about the strength of the association between 
the analysed variables and the outcomes.
CONCLUSIONS
This retrospective registry showed a high success 
rate and low incidence of adverse events in patients 
undergoing percutaneous stent implantation in the carotid 
and vertebral arteries. The present results indicate that 
the procedure can be executed safely and effectively 
when properly indicated, using the adequate technique 
and performed by qualified interventional professionals 
in tertiary centers.
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